ANI Pharmaceuticals Inc (OQ:ANIP)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 210 W Main St
BAUDETTE MN 56623-2467
Tel: N/A
IR: See website
Key People
Robert E. Brown
Independent Chairman of the Board
Arthur S. Przybyl
President, Chief Executive Officer, Director
Stephen P. Carey
Chief Financial Officer, Vice President - Finance
Robert W. Schrepfer
Senior Vice President -New Business Development and Specialty Sales
James G. Marken
Senior Vice President-Operations and Product Development
Business Overview
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.
Financial Overview
For the nine months ended 30 September 2019, ANI Pharmaceuticals Inc revenues increased 10% to $158.6M. Net income applicable to common stockholders increased 8% to $10.8M. Revenues reflect United States segment increase from $49M to $153.1M, Canada segment increase from $1.7M to $5.5M. Net income was partially offset by Depreciation and amortization increase of 40% to $35M (expense), Selling.
Employees: 299 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $869.81M as of Sep 30, 2019
Annual revenue (TTM): $215.70M as of Sep 30, 2019
EBITDA (TTM): $76.57M as of Sep 30, 2019
Net annual income (TTM): $16.13M as of Sep 30, 2019
Free cash flow (TTM): $62.12M as of Sep 30, 2019
Net Debt Last Fiscal Year: $126.94M as of Sep 30, 2019
Shares outstanding: 12,090,985 as of Oct 30, 2019
Index Membership: S&P 600 Small Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization